Leptospirosis
20
5
6
6
Key Insights
Highlights
Success Rate
86% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
5.0%
1 terminated out of 20 trials
85.7%
-0.8% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (20)
Preventive Strategies for Early and Late Complications of Leptospirosis
Xpert® Tropical Fever Test on GeneXpert® Edge X System
Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective
Leptospirosis Registry - LeptoScope
Leptospirosis Care Bundle Study
Characterizing the Host Response to Leptospirosis for Better Diagnosis and Prognosis - NIHFI
Serological Measurement of Montpellier Professionals' Contacts with Infectious Agents Responsible for Animal-borne Diseases
Seroprevalence of Leptospirosis in Val Müstair, Switzerland
Cohort of Hospitalized Patients Suspected of Leptospirosis
Study of the Innate Immune Response to the Acute Phase of Human Leptospirosis - IMMUNOLEPTO
Chronic Post-leptospirosis Manifestations in Reunion
Study of the Incidence of Jarisch-Herxheimer Reaction in Leptospirosis Patients in New Caledonia
Study of Decreasing Kinetics of the Leptospiremia During Antibiotic Treatment of Leptospirosis in Martinique
Severe Leptospirosis in Non-tropical Areas
Seroprevalence Study to Evaluate the Persistence of Anti-leptospira Antibody in Subjects Vaccinated With Spirolept® Vaccine
French West Indies Leptospirosis Study
The Sero-Prevalence and Genetic Study for the Infectious Diseases and Metabolic Syndrome in Solomon Islands
Rapid Diagnostic Tests and Clinical/Laboratory Predictors of Tropical Diseases In Patients With Persistent Fever in Cambodia, Nepal, Democratic Republic of the Congo and Sudan (NIDIAG-Fever)
Immune Response After Leptospirosis Infection
Desmopressin and Dexamethasone Adjunctive Treatment for Leptospirosis